Bio-Techne's Exosome Diagnostics Lab Receives Accreditation From College of American Pathologists (CAP) Bio-Techne Corporation (NASDAQ:TECH) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded...
Tuesday, December 17, 2019 1 min read
Key Takeaway: MINNEAPOLIS , Dec. 17, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a rece
Full Press Release Details
MINNEAPOLIS , Dec. 17, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a recent on-site inspection as part of the CAP's Accreditation Program. ExosomeDx was advised of this national recognition and congratulated for the excellence of services being provided. ExosomeDx is now one of more than 8,000 CAP-accredited facilities worldwide.
About Bio-Techne Corporation (NASDAQ: TECH )
Contact:
David Clair, Senior Director, Corporate Development